^
No biomarker
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
Eisai Press Release - 1 day
No biomarker
RCC
pembrolizumab + lenvatinib
Sensitive: A1 - Approval
Eisai Press Release - 1 day
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
Dovepress - 3 days
HER-2 positive
CRC
HER2-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
Cell Death Dis - 3 days
No biomarker
Esophageal Cancer
nivolumab
Sensitive: A1 - Approval
Ono Pharmaceuticals Press Release - 5 days
No biomarker
Gastric Cancer
nivolumab
Sensitive: A1 - Approval
Ono Pharmaceuticals Press Release - 5 days
HER-2 positive
Salivary Gland Cancer
trastuzumab
Sensitive: A1 - Approval
Chugai Press Release - 5 days
Chr t(5;7;7)(q33.2;q32;q11.2)
AML
imatinib
Sensitive: C4 – Case Studies
Dovepress - 5 days
CD20 negative
Diffuse Large B Cell Lymphoma
GDP
Sensitive: C4 – Case Studies
University of Oxford - 5 days
CD20 negative
Diffuse Large B Cell Lymphoma
EPOCH
Resistant: C4 – Case Studies
University of Oxford - 5 days
BRAF V600E
Glioma
trametinib + dabrafenib
Sensitive: C1 - Off-label
Lancet Oncol - 6 days
HER-2 expression
Gastric Cancer
AST-301
Sensitive: C2 – Inclusion Criteria
J Immunother Cancer - 6 days
No biomarker
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: A1 - Approval
BeiGene Press Release - 1 week
No biomarker
Triple Negative Breast Cancer
sacituzumab govitecan-hziy
Sensitive: A1 - Approval
Gilead Press Release - 1 week
No biomarker
GIST
ripretinib
Sensitive: A1 - Approval
Deciphera Pharmaceuticals Press Release - 1 week
No biomarker
RCC
pembrolizumab
Sensitive: A1 - Approval
FDA - 1 week
No biomarker
Melanoma
BNT111
Sensitive: A1 - Approval
BioNTech Press Release - 1 week
No biomarker
CRC
arfolitixorin
Sensitive: B - Late Trials
Isofol Medical Press Release - 1 week
KRAS A146 + TMB-H
CRC
bevacizumab
Sensitive: B - Late Trials
JCO Precis Oncol - 1 week
CD19 positive
B Acute Lymphoblastic Leukemia
CTX110
Sensitive: B - Late Trials
CRISPR Therap Press Release - 1 week
CD19 positive
NHL
CTX110
Sensitive: B - Late Trials
CRISPR Therap Press Release - 1 week
HR positive
HER2 Negative Breast Cancer
paclitaxel + cyclophosphamide oral + epirubicin
Sensitive: B - Late Trials
Eur J Cancer - 1 week
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
osimertinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
tepotinib
Sensitive: A1 - Approval
RET fusion
NSCLC
pralsetinib
Sensitive: A1 - Approval
Roche Press Release - 1 week
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A1 - Approval
N Z Med J - 1 week
PD-L1 expression
Triple Negative Breast Cancer
pembrolizumab
Sensitive: A1 - Approval
BioSpace - 1 week
BRCA1 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
Cancer Discov - 1 week
BRCA2 mutation
Ovarian Cancer
olaparib
Sensitive: A1 - Approval
Cancer Discov - 1 week
EGFR T790M
NSCLC
aumolertinib
Sensitive: A1 - Approval
HR positive
HER2 Positive Breast Cancer
trastuzumab
Sensitive: A2 - Guideline
Clin Cancer Res - 1 week
PD-L1 expression
NSCLC
MT-6402
Sensitive: B - Late Trials
Molecular Templates Press Release - 1 week
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive: B - Late Trials
Ann Oncol - 1 week
PD-L1 underexpression
Lung Non-Small Cell Squamous Cancer
nivolumab + ipilimumab
Sensitive: C1 - Off-label
Thorac Cancer - 1 week
HR negative
HER2 Positive Breast Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
Cancers (Basel) - 1 week
BCL2 amplification
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
Cancer Biol Med - 1 week
TP53 mutation
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
Cancer Biol Med - 1 week
miR-142 overexpression
Ovarian Cancer
bevacizumab
Sensitive: C3 – Early Trials
J Ovarian Res - 1 week
PD-L1 underexpression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: C3 – Early Trials
Thorac Cancer - 1 week
miR-25 underexpression
Ovarian Cancer
bevacizumab
Sensitive: C3 – Early Trials
J Ovarian Res - 1 week
HER-2 negative
Gastric Adenocarcinoma
cisplatin + paclitaxel + capecitabine
Sensitive: C3 – Early Trials
Asia Pac J Clin Oncol - 1 week
HER-2 D769Y
LUAD
afatinib + anlotinib
Sensitive: C4 – Case Studies
World J Surg Oncol - 1 week
EGFR E709_T710delinsD
NSCLC
afatinib
Sensitive: C4 – Case Studies
J Med Case Rep - 1 week
H3.3K27M
Glioma
anlotinib
Sensitive: C4 – Case Studies
Acta Neurochir (Wien) - 1 week
HER-2 amplification
CRC
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
AFP elevation
HCC
regorafenib
Sensitive: B - Late Trials
Cancer Med - 2 weeks
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A1 - Approval
KRAS G12C
NSCLC
sotorasib
Sensitive: A1 - Approval
BCR-ABL1 T315I
CML
asciminib
Sensitive: A1 - Approval
FDA - 4 weeks
PD-L1 expression
Cervical Cancer
pembrolizumab
Sensitive: A1 - Approval
N Engl J Med - 2 weeks
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
Target Oncol - 2 weeks
PD-L1 expression
Cervical Cancer
pembrolizumab + bevacizumab
Sensitive: A1 - Approval
N Engl J Med - 2 weeks
HER-2 negative
HER2 Negative Breast Cancer
LY2780301
Sensitive: C2 – Inclusion Criteria
Eur J Cancer - 2 weeks
TMB-H
NSCLC
PD-L1 inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 2 weeks
MET amplification
NSCLC
c-MET inhibitor
Sensitive: C3 – Early Trials
Exp Hematol Oncol - 2 weeks
MCT1 overexpression
Multiple Myeloma
lenalidomide
Resistant: C3 – Early Trials
Blood Adv - 2 weeks
TP53 mutation
Ovarian Cancer
modafinil
Sensitive: C3 – Early Trials
Cancer Gene Ther - 2 weeks
ACTA2 overexpression
HER2 Positive Breast Cancer
trastuzumab
Resistant: C3 – Early Trials
Clin Cancer Res - 2 weeks
TP53 mutation
Ovarian Cancer
Immunotherapy
Sensitive: C3 – Early Trials
Cancer Gene Ther - 2 weeks
BCL2 overexpression
Diffuse Large B Cell Lymphoma
R-CHOP
Resistant: C3 – Early Trials
Mod Pathol - 2 weeks
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD1 inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 2 weeks
TMB-H
NSCLC
PD1 inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 2 weeks
EGFR L747_T751delinsP
NSCLC
EGFR inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 2 weeks
PIK3CA Q75E
SCCHN
alpelisib
Sensitive: C4 – Case Studies
J Clin Invest - 2 weeks
EGFR L861R
Lung Cancer
bevacizumab + afatinib
Sensitive: C4 – Case Studies
Medicine (Baltimore) - 2 weeks
PD-L1 expression + EGFR mutation
NSCLC
pembrolizumab
Sensitive: C4 – Case Studies
J Oncol Pharm Pract - 2 weeks
TP53 mutation
HCC
AZD5363 + AZD8055
Sensitive: D – Preclinical
Cell Death Dis - 2 weeks
miR-200b underexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 2 weeks
miR-199b overexpression +miR-152 overexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 2 weeks
miR-152 overexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 2 weeks
miR-199b overexpression
Gastric Cancer
5-fluorouracil
Sensitive: D – Preclinical
DNA Cell Biol - 2 weeks
miR-103a underexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 2 weeks
miR-200b underexpression + miR-103a underexpression
Gastric Cancer
5-fluorouracil
Resistant: D – Preclinical
DNA Cell Biol - 2 weeks
IDH1 mutation
AML
ivosidenib
Sensitive: A1 - Approval
ASH 2021 - 3 weeks
PD-L1 overexpression
NSCLC
pembrolizumab
Sensitive: A2 - Guideline
IDH1 mutation
AML
venetoclax
Sensitive: A2 - Guideline
Research Square - 3 weeks
FLT3-ITD mutation
AML
midostaurin
Sensitive: A2 - Guideline
ASH 2021 - 3 weeks
MSI-H/dMMR
Endometrial Cancer
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
NCCN - 3 weeks
BCR-ABL1 T315I
CML
HQP1351
Sensitive: B - Late Trials
ASH 2021 - 3 weeks
Chr t(11;14)
Multiple Myeloma
venetoclax + bortezomib
Sensitive: B - Late Trials
ASH 2021 - 3 weeks
BCR-ABL1 fusion
CML
asciminib
Sensitive: B - Late Trials
ASH 2021 - 3 weeks
HR positive
HER2 Negative Breast Cancer
CDK6 inhibitor
Sensitive: B - Late Trials
JAMA Netw Open - 3 weeks
HR positive
HER2 Negative Breast Cancer
CDK4 inhibitor
Sensitive: B - Late Trials
JAMA Netw Open - 3 weeks
KRAS mutation
NSCLC
Immunotherapy
Sensitive: B - Late Trials
SITC 2021 - 3 weeks
FLT3 mutation
AML
FLT3 inhibitor
Sensitive: B - Late Trials
No biomarker
Diffuse Large B Cell Lymphoma
EZM0414
Sensitive: B - Late Trials
Epizyme Press Release - 3 weeks
RAB5A expression
Breast Cancer
ado-trastuzumab emtansine
Sensitive: B - Late Trials
Nature - 3 weeks
TP53 mutation
CLL
BR
Resistant: B - Late Trials
ASH 2021 - 3 weeks
No biomarker
Cholangiocarcinoma
TT-00420
Sensitive: B - Late Trials
PRNewswire - 3 weeks
STK11 mutation
NSCLC
BGB324
Sensitive: B - Late Trials
BerGenBio Press Release - 3 weeks
STK11 mutation
NSCLC
pembrolizumab + BGB324
Sensitive: B - Late Trials
SITC 2021 - 3 weeks
PD-L1 expression
NSCLC
atezolizumab
Sensitive: A1 - Approval
EGFR T790M
NSCLC
osimertinib
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ALK positive
NHL
crizotinib
Sensitive: A1 - Approval
FLT3 mutation
AML
gilteritinib
Sensitive: A1 - Approval
HR positive
HER2 Negative Breast Cancer
palbociclib
Sensitive: A1 - Approval
J Comp Eff Res - 3 weeks
FLT3 mutation
AML
midostaurin
Sensitive: A1 - Approval
CD22 positive
B Acute Lymphoblastic Leukemia
inotuzumab ozogamicin
Sensitive: A1 - Approval
CD19 positive
ALL
blinatumomab
Sensitive: A1 - Approval
BCR-ABL1 fusion
CML
bosutinib
Sensitive: A1 - Approval
ASH 2021 - 3 weeks
Chr del(17p)
CLL
acalabrutinib
Sensitive: A1 - Approval
IDH2 mutation
AML
venetoclax
Sensitive: A2 - Guideline
Research Square - 3 weeks
FLT3 mutation
AML
venetoclax
Sensitive: A2 - Guideline
HR positive
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
Nature - 3 weeks
TP53 mutation
CLL
ibrutinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib
Sensitive: A2 - Guideline
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
ponatinib
Sensitive: A2 - Guideline
TP53 mutation
MDS
APR-246
Sensitive: B - Late Trials
ASH 2021 - 3 weeks
TP53 mutation
AML
APR-246
Sensitive: B - Late Trials
ASH 2021 - 3 weeks
NPM1 mutation
AML
venetoclax
Sensitive: B - Late Trials
Research Square - 3 weeks
TP53 mutation
AML
venetoclax
Resistant: B - Late Trials
ASH 2021 - 3 weeks
HR positive
HER2 Negative Breast Cancer
SHR6390
Sensitive: B - Late Trials
Nat Med - 3 weeks
NPM1 mutation
AML
azacitidine
Sensitive: B - Late Trials
ASH 2021 - 3 weeks
FLT3 mutation
Leukemia
midostaurin
Sensitive: B - Late Trials
ASH 2021 - 3 weeks
TNFRSF8 positive
Peripheral T-cell Lymphoma
brentuximab vedotin
Sensitive: B - Late Trials
ASH 2021 - 3 weeks
IDH2 mutation
ALL
enasidenib
Sensitive: B - Late Trials
ASH 2021 - 3 weeks
TMB-H
NSCLC
pembrolizumab
Sensitive: C1 - Off-label
SITC 2021 - 3 weeks
PD-L1 expression
Triple Negative Breast Cancer
trilaciclib
Sensitive: C2 – Inclusion Criteria
SITC 2021 - 3 weeks
CCND1 overexpression
Mantle Cell Lymphoma
INCB50465
Sensitive: C2 – Inclusion Criteria
ASH 2021 - 3 weeks
PD-L1 expression
Urothelial Cancer
toripalimab
Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 3 weeks
TP53 mutation
MDS
venetoclax
Sensitive: C2 – Inclusion Criteria
ASH 2021 - 3 weeks
ASXL1 mutation
MDS
venetoclax
Sensitive: C2 – Inclusion Criteria
ASH 2021 - 3 weeks
EGFR T790M
NSCLC
STI-5656
Sensitive: C2 – Inclusion Criteria
FLT3-ITD mutation
AML
venetoclax + quizartinib
Sensitive: C2 – Inclusion Criteria
ASH 2021 - 3 weeks
BCL2 expression
NHL
venetoclax
Sensitive: C2 – Inclusion Criteria
ASH 2021 - 3 weeks
IDH1 R132
AML
ivosidenib
Sensitive: C2 – Inclusion Criteria
ASH 2021 - 3 weeks
FLT3 mutation
AML
azacitidine
Sensitive: C2 – Inclusion Criteria
FLT3 mutation
AML
FLT3 inhibitor + gilteritinib
Sensitive: C2 – Inclusion Criteria
MLL rearrangement
Leukemia
SNDX-5613
Sensitive: C2 – Inclusion Criteria
ASH 2021 - 3 weeks
NPM1 mutation
Leukemia
SNDX-5613
Sensitive: C2 – Inclusion Criteria
ASH 2021 - 3 weeks
TP53 mutation
Mantle Cell Lymphoma
venetoclax + obinutuzumab + zanubrutinib
Sensitive: C2 – Inclusion Criteria
ASH 2021 - 3 weeks
TP53 mutation
AML
venetoclax + GS-4721
Sensitive: C2 – Inclusion Criteria
ASH 2021 - 3 weeks
FLT3 mutation
MDS
quizartinib
Sensitive: C2 – Inclusion Criteria
CBL mutation
MDS
quizartinib
Sensitive: C2 – Inclusion Criteria
ASH 2021 - 3 weeks
TP53 mutation
CLL
ibrutinib + rituximab
Sensitive: C2 – Inclusion Criteria
ASH 2021 - 3 weeks
PD-L1 expression
Nasopharyngeal Carcinoma
sintilimab
Sensitive: C2 – Inclusion Criteria
Front Immunol - 3 weeks
MSLN positive
Mesothelioma
TC-210
Sensitive: C2 – Inclusion Criteria
HER-2 amplification
NSCLC
pyrotinib
Sensitive: C2 – Inclusion Criteria
Clin Cancer Res - 3 weeks
PD-L1 overexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
ASXL1 mutation
CML
Tyrosine kinase inhibitor
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr t(11;14)
Multiple Myeloma
bortezomib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
AML
venetoclax + MLN4924
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
CLL
ICP-022
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
FLT3-ITD mutation
AML
venetoclax
Sensitive: C3 – Early Trials
Research Square - 3 weeks
IDH1 mutation
AML
FT-2102
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
AML
cytarabine/daunorubicin liposomal formulation
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
BCR-ABL1 T315I
CML
PF-114
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
ALK positive
NHL
alectinib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
HER-2 positive
Gastric Cancer
trastuzumab + ramucirumab + ALX148
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
DNMT3A mutation
AML
venetoclax + gilteritinib
Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
FLT3 mutation
AML
venetoclax + gilteritinib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr del(17p)
Small Lymphocytic Lymphoma
ICP-022
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
Small Lymphocytic Lymphoma
ICP-022
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr del(11q)
Small Lymphocytic Lymphoma
ICP-022
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr del(17p)
CLL
ICP-022
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr del(11q)
CLL
ICP-022
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr del(17p)
Multiple Myeloma
bortezomib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
NFKB2 negative
Multiple Myeloma
ixazomib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
BTK C481
CLL
LOXO-305
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr del(17p)
Multiple Myeloma
thalidomide
Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
Chr amplification(1)(q21)
Multiple Myeloma
thalidomide
Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
RAB5A expression
Breast Cancer
ado-trastuzumab emtansine + pertuzumab
Sensitive: C3 – Early Trials
Nature - 3 weeks
CCR5 positive
Triple Negative Breast Cancer
leronlimab
Sensitive: C3 – Early Trials
CytoDyn Press Release - 3 weeks
HR negative
HER2 Positive Breast Cancer
trastuzumab + paclitaxel + pertuzumab
Sensitive: C3 – Early Trials
Nature - 3 weeks
HR negative
HER2 Positive Breast Cancer
ado-trastuzumab emtansine + pertuzumab
Sensitive: C3 – Early Trials
Nature - 3 weeks
HR positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine + pertuzumab
Sensitive: C3 – Early Trials
Nature - 3 weeks
TP53 mutation
MDS
ALX148
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
SF3B1 mutation
CLL
obinutuzumab + GS-9973
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
NOTCH1 mutation
CLL
obinutuzumab + GS-9973
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
CLL
obinutuzumab + GS-9973
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
RUNX1 mutation
CML
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
STAT5A mutation
CML
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
PHF6 mutation
CML
Tyrosine kinase inhibitor
Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
TNFRSF8 expression
Peripheral T-cell Lymphoma
CHEP-BV
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr t(11;14)
Mantle Cell Lymphoma
INCB50465
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
BTK C481
Small Lymphocytic Lymphoma
LOXO-305
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
NPM1 mutation
AML
venetoclax + gilteritinib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
NPM1 mutation + DNMT3A mutation
AML
venetoclax + gilteritinib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
CD19 positive
B Acute Lymphoblastic Leukemia
PBCAR0191
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
FGFR1 rearrangement
MDS
pemigatinib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
CXCL12 expression
Peripheral T-cell Lymphoma
tipifarnib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
CD22 overexpression
ALL
inotuzumab ozogamicin
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
CD22 underexpression+BCL2 overexpression
ALL
inotuzumab ozogamicin
Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
MYD88 L265P
Waldenstrom Macroglobulinemia
ICP-022
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
IDH2 mutation
AML
DCAG
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
FLT3-ITD mutation
AML
DCAG
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
DNMT3A mutation
AML
DCAG
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
AML
DCAG
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
NRAS mutation
AML
DCAG
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
CEBPA mutation
AML
DCAG
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
KMT2A rearrangement
Childhood B Acute Lymphoblastic Leukemia
blinatumomab
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
FLT3‐ITD mutation + DNMT3A mutation + NPM1 mutation
AML
sorafenib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
CD20 positive
Follicular Lymphoma
rituximab + lenalidomide + GEN3013
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 deletion
Mantle Cell Lymphoma
venetoclax + ibrutinib + rituximab
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
Mantle Cell Lymphoma
venetoclax + ibrutinib + rituximab
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
DNMT3A mutation
AML
RVU120
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
AML
venetoclax + lintuzumab-Ac225
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
AML
venetoclax + APR-246
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
AML
GS-9973
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
FLT3 mutation
AML
midostaurin + gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
IDH2 R140Q
AML
venetoclax + enasidenib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
IDH2 R172K
AML
venetoclax + enasidenib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
MDS
venetoclax + tagraxofusp
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
MDS
tagraxofusp
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
AML
venetoclax + tagraxofusp
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
AML
tagraxofusp
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
CD123 positive
AML
venetoclax + IMGN632
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
WT1 overexpression
MDS
cytarabine + decitabine + tretinoin
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
MDS
cytarabine + decitabine + tretinoin
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
ASXL1 mutation
MDS
cytarabine + decitabine + tretinoin
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
SRSF2 mutation
AML
AZD1775
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
SRSF2 mutation
AML
LY2606368
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
MYD88 mutation + CXCR4 mutation
Waldenstrom Macroglobulinemia
ibrutinib + X4P-001
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
DNMT3A mutation
Peripheral T-cell Lymphoma
CHOP
Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
ALK positive
NHL
ceritinib
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
LGALS1 overexpression + LAG3 overexpression
CLL
ibrutinib
Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
LGALS1 overexpression + LAG3 overexpression
CLL
OTX-008
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr t(11;14)
Multiple Myeloma
pomalidomide
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib + blinatumomab
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
HER-2 mutation
LUAD
Immunotherapy
Sensitive: C3 – Early Trials
Cancer Immunol Immunother - 3 weeks
BRAF mutation
Melanoma
PD1 inhibitor + BRAF inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
BRAF mutation
Melanoma
PD1 inhibitor + BRAF inhibitor + MEK inhibitor
Sensitive: C3 – Early Trials
BMC Cancer - 3 weeks
TMB-H
Urothelial Cancer
toripalimab
Sensitive: C3 – Early Trials
Clin Cancer Res - 3 weeks
FLT3-ITD mutation
AML
decitabine
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TMB-H
Follicular Lymphoma
venetoclax + obinutuzumab + bendamustine
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
NLRP3 mutation
Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
Aging (Albany NY) - 3 weeks
MAP2K1 mutation
Pancreatic Ductal Adenocarcinoma
avelumab + binimetinib
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 overexpression
Pancreatic Ductal Adenocarcinoma
avelumab + binimetinib
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
MAP2K2 mutation
Pancreatic Ductal Adenocarcinoma
avelumab + binimetinib
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PIK3CA mutation
Pancreatic Ductal Adenocarcinoma
avelumab + binimetinib
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
RNF43 mutation
Pancreatic Ductal Adenocarcinoma
avelumab + binimetinib
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
TMB-H
Solid Tumor
tislelizumab
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 overexpression
Mesothelioma
pembrolizumab + nintedanib
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 overexpression
HCC
durvalumab + cabozantinib tablet
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 overexpression
CRC
durvalumab + cabozantinib tablet
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 overexpression
Gastroesophageal Junction Adenocarcinoma
durvalumab + cabozantinib tablet
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
IDH2 mutation
GBM
AV-GBM-1
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
IDH1 mutation
GBM
AV-GBM-1
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
MGMT promoter methylation
GBM
AV-GBM-1
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
GDF15-L
Melanoma
PD1 inhibitor
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
TNFRSF14 overexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
TNFRSF18 overexpression
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
AR positive
Ovarian Cancer
enzalutamide
Sensitive: C3 – Early Trials
Gynecol Oncol - 3 weeks
CD28 overexpression
Lymphoma
mogamulizumab
Resistant: C3 – Early Trials
Cancer Sci - 3 weeks
CD28 overexpression
Leukemia
mogamulizumab
Resistant: C3 – Early Trials
Cancer Sci - 3 weeks
TMB-H
NSCLC
pembrolizumab + MK-1308
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
TMB-H
NSCLC
pembrolizumab + MK-4280
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PTEN underexpression
CLL
ibrutinib
Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
miR-543 overexpression
CLL
ibrutinib
Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
PD-L1-H + CXCL10-H + TNFA-H
Melanoma
nivolumab + ipilimumab
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
PD-L1 expression
Nasopharyngeal Carcinoma
AK104
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
BCR-ABL1 T315I
B Acute Lymphoblastic Leukemia
VPD
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
SIGLEC15 expression
Solid Tumor
NC318
Sensitive: C3 – Early Trials
SITC 2021 - 3 weeks
miR-494 overexpression
CLL
ibrutinib
Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
miR-495 overexpression
CLL
ibrutinib
Resistant: C3 – Early Trials
Cell Death Dis - 3 weeks
IFIT3 overexpression
Cutaneous Melanoma
dasatinib
Sensitive: C3 – Early Trials
Int Immunopharmacol - 3 weeks
IFIT1 overexpression
Cutaneous Melanoma
dasatinib
Sensitive: C3 – Early Trials
Int Immunopharmacol - 3 weeks
CD33 positive
AML
talazoparib + gemtuzumab ozogamicin
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr del(17p)
Multiple Myeloma
selinexor
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
TP53 mutation
CLL
BTK inhibitor
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
Chr del(17p)
CLL
BTK inhibitor
Sensitive: C3 – Early Trials
ASH 2021 - 3 weeks
SPN positive
Multiple Myeloma
bortezomib
Resistant: C3 – Early Trials
ASH 2021 - 3 weeks
ALK positive
NHL
CART-30
Resistant: C4 – Case Studies
ASH 2021 - 3 weeks
TP53 mutation + CARD11 mutation + SMARCA4 mutation
Mantle Cell Lymphoma
venetoclax + obinutuzumab + zanubrutinib
Sensitive: C4 – Case Studies
ASH 2021 - 3 weeks
KRAS G12D + HER-2 amplification + TMB-H
CRC
pembrolizumab
Sensitive: C4 – Case Studies
SITC 2021 - 3 weeks
CD20 expression + PAX5 expression + BCL2 expression
Marginal Zone Lymphoma
rituximab
Sensitive: C4 – Case Studies
Am Surg - 3 weeks
FGFR3 amplification
Gastric Adenocarcinoma
pazopanib
Sensitive: C4 – Case Studies
Clin Case Rep - 3 weeks
NBEA-ALK fusion + EML4-ALK fusion
LUAD
alectinib
Sensitive: C4 – Case Studies
Lung Cancer - 3 weeks
TP53 mutation
T Acute Lymphoblastic Leukemia
CD7-targeted CAR-T immunotherapy
Sensitive: C4 – Case Studies
ASH 2021 - 3 weeks
MUC1 expression
Ovarian Cancer
P-MUC1C-ALLO1
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
FLT3-ITD mutation + NRAS mutation + GATA2 mutation
AML
venetoclax
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
SRSF2 P95H
AML
E7107
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
PPP1R15B overexpression
Multiple Myeloma
salubrinal
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
FLT3-ITD mutation
AML
quizartinib + AZD1208
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
FLT3-ITD mutation
AML
quizartinib + GMI-1359
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
FLT3-ITD mutation
AML
gilteritinib + AZD1208
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
CD123 positive
AML
MGD024
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
LY9 expression
CLL
CAR-T immunotherapy
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
NPM1 mutation
AML
abemaciclib + KO-539
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
MLL mutation
AML
abemaciclib + KO-539
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
NPM1 mutation
AML
KO-539 + OTX015
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
MLL mutation
AML
KO-539 + OTX015
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
NPM1 mutation
AML
venetoclax + KO-539
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
MLL mutation
AML
venetoclax + KO-539
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
FLT3-ITD mutation
AML
pelareorep
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
FLT3-ITD mutation
AML
quizartinib + CC-90009
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
NPM1 expression
AML
SNDX-5613
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
NPM1 expression
AML
VTP-50469
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
MYC overexpression
Mantle Cell Lymphoma
venetoclax
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
CDKN2A overexpression
Mantle Cell Lymphoma
venetoclax
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
RB1 deletion
Mantle Cell Lymphoma
palbociclib
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
PAX5-JAK2 fusion
ALL
CHZ868
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
IL7R expression
B Acute Lymphoblastic Leukemia
OSE-127
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
BRCA mutation
Diffuse Large B Cell Lymphoma
loncastuximab tesirine
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
MLL rearrangement
B Acute Lymphoblastic Leukemia
OSE-127
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
OSE-127
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
SRSF2 P95L
MDS
CTX-712
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
SRSF2 P95L
AML
CTX-712
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
SRSF2 P95H
MDS
CTX-712
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
HMGA1 deletion+ JAK2 V617F
AML
ruxolitinib
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
KMT2A rearrangement
ALL
FLT3 inhibitor + gilteritinib
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
KMT2A expression
AML
SNDX-5613
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
KMT2A expression
AML
VTP-50469
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
TCF3-PBX1 fusion
B Acute Lymphoblastic Leukemia
OSE-127
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
BCR-ABL1 T315I
ALL
venetoclax
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
KRAS mutation
ALL
venetoclax
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
CD74 expression
ALL
STRO-001
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
CD74 expression
AML
STRO-001
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
RNF31 deletion
Leukemia
tamoxifen
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
CRLF2 rearrangement
ALL
T-lymphocyte cell therapy
Sensitive: D – Preclinical
ASH 2021 - 3 weeks
FGFR3 G370C
Bladder Cancer
PD-L1 inhibitor
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
BCR-ABL1 fusion
ALL
PD-L1 inhibitor + nilotinib
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
HER-2 positive
HER2 Positive Breast Cancer
HER2-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
EGFR expression
SCCHN
cetuximab + CYNK-101
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
EGFR expression
NSCLC
cetuximab + CYNK-101
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
FGFR3 K508M
Bladder Cancer
PD-L1 inhibitor
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
TPBG expression
Solid Tumor
ALG.APV-527
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
CLDN18.2 expression
Solid Tumor
TJ-CD4B
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
ICAM1 overexpression
Breast Cancer
AIC100
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
ICAM1 overexpression
Multiple Myeloma
AIC100
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
ICAM1 overexpression
Gastric Cancer
AIC100
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
HER-2 positive
HER2 Positive Breast Cancer
AB-201
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
MUC1 expression
Breast Cancer
P-MUC1C-ALLO1
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
MSLN overexpression + PD-L1 overexpression
Mesothelioma
ATA3271
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
CLDN18.2 positive
Gastric Cancer
CLDN18.2-targeted CAR-T immunotherapy
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
BAP1 mutation
Solid Tumor
BET inhibitor
Sensitive: D – Preclinical
Acta Pharmacol Sin - 3 weeks
PD-L1 expression
Solid Tumor
SGN-PDL1V
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
VTCN1 expression
Breast Cancer
SGN-B7H4V
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
VTCN1 expression
Ovarian Cancer
SGN-B7H4V
Sensitive: D – Preclinical
SITC 2021 - 3 weeks
BCR-ABL1 fusion
B Acute Lymphoblastic Leukemia
dasatinib + SBI-756
Sensitive: D – Preclinical
Sci Rep - 3 weeks
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
lisocabtagene maraleucel
Sensitive: A1 - Approval
CD20 positive
CLL
Truxima (rituximab biosimilar)
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
afatinib
Sensitive: A1 - Approval
No biomarker
NSCLC
ramucirumab
Sensitive: A1 - Approval
ALK positive
NSCLC
lorlatinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
gefitinib
Sensitive: A1 - Approval
PD-L1 expression
Triple Negative Breast Cancer
atezolizumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
afatinib
Sensitive: A1 - Approval
No biomarker
NSCLC
durvalumab
Sensitive: A1 - Approval
ALK positive
NSCLC
alectinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
trastuzumab + tucatinib
Sensitive: A1 - Approval
HER-2 amplification
Breast Cancer
neratinib
Sensitive: A1 - Approval
KIT positive
GIST
imatinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
margetuximab
Sensitive: A1 - Approval
No biomarker
RCC
nivolumab + cabozantinib tablet
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
ALK fusion
NSCLC
brigatinib
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
trastuzumab
Sensitive: A1 - Approval
No biomarker
Follicular Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
No biomarker
Mediastinal B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: A1 - Approval
PDGFRA D842V
GIST
avapritinib
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Esophageal Squamous Cell Carcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
Fallopian Tube Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Ovarian Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Peritoneal Cancer
niraparib
Sensitive: A1 - Approval
No biomarker
Mantle Cell Lymphoma
brexucabtagene autoleucel
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
MSI-H/dMMR
Solid Tumor
dostarlimab
Sensitive: A1 - Approval
No biomarker
Esophageal Adenocarcinoma
nivolumab
Sensitive: A1 - Approval
No biomarker
NHL
brentuximab vedotin
Sensitive: A1 - Approval
ALK positive
NSCLC
brigatinib
Sensitive: A1 - Approval
ROS1 fusion
NSCLC
entrectinib
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
No biomarker
NSCLC
bevacizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
dacomitinib
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
EGFR T790M
NSCLC
lazertinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
dacomitinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
capmatinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
cemiplimab
Sensitive: A1 - Approval
Sanofi Press Release - 4 weeks
No biomarker
SCCHN
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastric Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + 5-fluorouracil + docetaxel
Sensitive: A1 - Approval
No biomarker
NSCLC
cisplatin + pemetrexed
Sensitive: A1 - Approval
No biomarker
Breast Cancer
docetaxel + doxorubicin hydrochloride + cyclophosphamide oral
Sensitive: A1 - Approval
No biomarker
BCC
fluorouracil topical
Sensitive: A1 - Approval
PD-L1 expression
Urothelial Cancer
atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
gefitinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
carfilzomib
Sensitive: A1 - Approval
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A1 - Approval
ALK positive
NSCLC
crizotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
crizotinib
Sensitive: A1 - Approval
RET fusion
NSCLC
selpercatinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
mobocertinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
HER-2 positive
Gastric Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
HER-2 positive
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
BRCA2 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
durvalumab
Sensitive: A1 - Approval
IDH2 mutation
AML
enasidenib
Sensitive: A1 - Approval
No biomarker
AML
glasdegib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
erlotinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
HCC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
HCC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
bortezomib + panobinostat
Sensitive: A1 - Approval
No biomarker
Multiple Myeloma
bortezomib + pegylated liposomal doxorubicin
Sensitive: A1 - Approval
BRCA1 mutation
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
rituximab
Sensitive: A1 - Approval
HER-2 positive
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
FGFR2 rearrangement
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
No biomarker
NSCLC
tislelizumab
Sensitive: A1 - Approval
No biomarker
Lymphoma
axicabtagene ciloleucel
Resistant: A1 - Approval
No biomarker
Diffuse Large B Cell Lymphoma
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
Childhood B Acute Lymphoblastic Leukemia
tisagenlecleucel-T
Sensitive: A1 - Approval
No biomarker
Prostate Cancer
apalutamide
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
IDH1 mutation
Cholangiocarcinoma
ivosidenib
Sensitive: A1 - Approval
MSI-H/dMMR
CRC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
CLL
ibrutinib + rituximab
Sensitive: A1 - Approval